$7.070
+0.030 (+0.43%)收盤時
- High
- 7.100
- Open
- 7.000
- VWAP
- 6.97
- Vol
- 176.91K
- Mkt Cap
- —
- Low
- 6.730
- Amount
- 1.23M
- EV/EBITDA, TTM
- 0.00
Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.
AI analysis of Conexeu Sciences Inc (CNXU)
buyConexeu Sciences Inc. (CNXU) is a good buy right now due to its recent completion of a significant preclinical study, which has the potential to drive its entry into the $11 billion medical aesthetics market. The stock has a current price of $7.07, which is well below the analyst price target of $20, indicating a potential upside of over 182%. Additionally, the RSI is at 31.091, suggesting that the stock is currently oversold, which could present a buying opportunity. However, the main risk is the company's negative net income of -2,304,283 USD in Q2 2026, indicating ongoing financial challenges that investors should consider.
估值指標
事件時間軸
資訊
8.508-18NewsfilterConexeu Sciences Inc. Pioneers New Regenerative Medicine Category
- 5.008-18Newsfilter
Redefining Categories in Medical Aesthetics
- 8.508-18Newsfilter
Conexeu Advances New Frontier in Regenerative Medicine
- 8.508-12Newsfilter
Conexeu Sciences Targets Regenerative Medicine Market with Innovative Platform
- 8.508-11Newsfilter
Conexeu Sciences Unveils New Extracellular Matrix Technology
CNXU FAQ — answered by Alphio AI
Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics. It operates in the Healthcare sector.
Conexeu Sciences Inc. (CNXU) is a good buy right now due to its recent completion of a significant preclinical study, which has the potential to drive its entry into the $11 billion medical aesthetics market. The stock has a current price of $7.07, which is well below the analyst price target of $20, indicating a potential upside of over 182%. Additionally, the RSI is at 31.091, suggesting that the stock is currently oversold, which could present a buying opportunity. However, the main risk is the company's negative net income of -2,304,283 USD in Q2 2026, indicating ongoing financial challenges that investors should consider.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。